Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:33:33.474Z.
Calculation as of: 2026-10-06T22:33:33.474Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 97452f2638ad5d60f1716ef7360feea6a822b872a50cf44a9ba771f9e60b5836
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$10.19B
EBITDA Yield
5.07%
TTM Avg
12.31%
3Y Avg
11.97%
5Y Avg
10.44%
Market Cap
$10.13B
EBITDA Yield
8.81%
TTM Avg
7.21%
3Y Avg
5.79%
5Y Avg
5.02%
Market Cap
$10.72B
EBITDA Yield
17.04%
TTM Avg
15.52%
3Y Avg
12.98%
5Y Avg
12.69%
Market Cap
$10.03B
EBITDA Yield
4.84%
TTM Avg
4.19%
3Y Avg
4.22%
5Y Avg
4.75%
Market Cap
$10.87B
EBITDA Yield
3.00%
TTM Avg
5.63%
3Y Avg
4.15%
5Y Avg
2.81%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Twist Bioscience Corporation (TWST) | $10.40B | N/A | N/A | N/A | N/A |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 9.42% | 6.93% | 5.23% | 4.87% |
| 10x Genomics, Inc. (TXG)vs › | $10.24B | N/A | 0.19% | 0.19% | 0.19% |
| Molina Healthcare, Inc. (MOH)vs › | $10.19B | 5.07% | 12.31% | 11.97% | 10.44% |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 8.81% | 7.21% | 5.79% | 5.02% |
| Universal Health Services, Inc. (UHS)vs › | $10.72B | 17.04% | 15.52% | 12.98% | 12.69% |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 4.84% | 4.19% | 4.22% | 4.75% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.87B | 3.00% | 5.63% | 4.15% | 2.81% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 3.60% | 4.56% | 5.12% | 4.77% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
